Stockscreener 앱 받기
128.56
0.38%
0.51
전일 마감가:
$128.05
열려 있는:
$128.075
하루 거래량:
2.85M
Relative Volume:
0.47
시가총액:
$223.55B
수익:
$43.84B
순이익/손실:
$13.90B
주가수익비율:
16.13
EPS:
7.9725
순현금흐름:
$6.92B
1주 성능:
+1.89%
1개월 성능:
+1.33%
6개월 성능:
-2.11%
1년 성능:
+8.96%
1일 변동 폭
$127.02
$129.01
1주일 범위
$122.09
$129.52
52주 변동 폭
$110.86
$140.84
애보트 래버러토리스 Stock (ABT) Company Profile
명칭
Abbott Laboratories
전화
(224) 667-6100
주소
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
128.56 | 222.66B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
101.05 | 150.26B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
371.06 | 143.44B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
105.06 | 135.12B | 34.76B | 4.79B | 5.21B | 3.7049 |
|
EW
Edwards Lifesciences Corp
|
86.89 | 50.38B | 5.88B | 1.34B | 799.60M | 2.3489 |
애보트 래버러토리스 Stock (ABT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-10 | 개시 | The Benchmark Company | Buy |
| 2025-07-18 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-06-16 | 개시 | Leerink Partners | Market Perform |
| 2024-10-08 | 개시 | Oppenheimer | Outperform |
| 2024-09-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 다운그레이드 | Edward Jones | Buy → Hold |
| 2024-05-30 | 개시 | Goldman | Buy |
| 2023-07-21 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2023-05-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-20 | 재확인 | Barclays | Overweight |
| 2023-04-20 | 재확인 | Bernstein | Outperform |
| 2023-04-20 | 재확인 | JP Morgan | Overweight |
| 2023-04-20 | 재확인 | Raymond James | Outperform |
| 2023-04-20 | 재확인 | UBS | Buy |
| 2023-04-20 | 재확인 | Wolfe Research | Underperform |
| 2023-03-29 | 개시 | UBS | Buy |
| 2022-10-26 | 개시 | Mizuho | Neutral |
| 2022-10-18 | 개시 | Barclays | Overweight |
| 2022-10-12 | 개시 | Jefferies | Hold |
| 2022-07-06 | 개시 | Wolfe Research | Underperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-01-27 | 재확인 | Credit Suisse | Outperform |
| 2022-01-27 | 재확인 | Morgan Stanley | Overweight |
| 2022-01-27 | 재확인 | Raymond James | Outperform |
| 2022-01-27 | 재확인 | UBS | Buy |
| 2021-12-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-10-27 | 업그레이드 | Atlantic Equities | Neutral → Overweight |
| 2021-10-14 | 개시 | Redburn | Neutral |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Neutral |
| 2021-01-28 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-09-11 | 개시 | Wolfe Research | Outperform |
| 2020-06-01 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2020-02-13 | 개시 | Goldman | Neutral |
| 2020-02-06 | 재개 | BTIG Research | Neutral |
| 2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2019-06-13 | 재확인 | BofA/Merrill | Buy |
| 2019-02-07 | 재확인 | BofA/Merrill | Buy |
| 2019-01-02 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2018-11-30 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-16 | 개시 | Barclays | Overweight |
| 2018-06-27 | 개시 | Bernstein | Outperform |
| 2018-01-30 | 재확인 | Citigroup | Neutral |
| 2018-01-25 | 재확인 | Stifel | Buy |
| 2018-01-25 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2018-01-03 | 개시 | Evercore ISI | Outperform |
| 2018-01-02 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-10-19 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-10-19 | 재확인 | Stifel | Buy |
모두보기
애보트 래버러토리스 주식(ABT)의 최신 뉴스
Abbott Accused Of Miscalculating Workers' Overtime - Law360
Assessing Abbott Laboratories (ABT) Valuation Following Steady 2024 Gains and Analyst Growth Projections - simplywall.st
Is Abbott Laboratories Stock Underperforming the S&P 500? - Yahoo Finance
Abbott Laboratories (ABT) Valuation in Focus After Renewed Trading Momentum - Yahoo Finance
Top Abbott Exec Cashes In on Stock Sale! - TipRanks
Insider Sell: Eric Shroff Sells Shares of Abbott Laboratories (A - GuruFocus
Abbott’s $23B Bet on Exact Sciences: Bold Move or Risky Gamble? - MedCity News
Abbott Laboratories SVP Shroff sells $203k in stock - Investing.com India
Abbott shares safety concerns with millions of CGM sensors—7 deaths reported - Cardiovascular Business
Abbott to replace glucose monitors after deaths possibly linked to false readings - Crain's Chicago Business
Abbott Laboratories Limited Appoints Brian William Jordan as A New Director, Effective November 25, 2025 - MarketScreener
Exact Sciences stock rating downgraded to Hold by TD Cowen following Abbott deal - Investing.com
Canaccord Genuity downgrades Exact Sciences stock to Hold after Abbott deal - Investing.com India
Abbott issues US device correction for some glucose monitors over faulty readings risk - WTAQ
Abbott's Exact Sciences Acquisition Signals Maturation of Single-Site Specialty Dx Space - 360Dx
Abbott Laboratories Issues Correction on 3 Million Glucose Sensors Over Possible Faulty Readings - NTD News
Abbott mum on malfunction behind Freestyle Libre 3 recall - BioWorld MedTech
Abbott issues correction for millions of glucose sensors - MedTech Dive
Key facts: Abbott Labs to acquire Exact Sciences for $23 billion; recalls FreeStyle Libre 3 sensors - TradingView
Abbott issues medical device correction for some glucose monitors in U.S. - MarketScreener
Abbott is buying Exact Sciences. Here’s why - Modern Healthcare
Jefferies cuts Exact Sciences to 'hold' after Abbott acquisition - TradingView
Is Weakness In Abbott Laboratories (NYSE:ABT) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Jefferies downgrades Exact Sciences stock to Hold after Abbott acquisition - Investing.com
Jim Cramer on Abbott: “I Think It’s a Terrific Time to Do Some Buying” - MSN
Jim Cramer on Abbott: "I Think It's a Terrific Time to Do Some Buying" - Finviz
Exact Sciences (EXAS) Shares Surge on Abbott Acquisition Deal - GuruFocus
Notable healthcare headlines for the week: Abbott, Medtronic, Merck and J&J in focus - MSN
Abbott’s (ABT) Exact Sciences Deal is “Very, Very Important,” Says Jim Cramer - MSN
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
Abbott acquires cancer diagnostic company Exact Sciences for $21B - HealthExec
William Blair Remains a Buy on Abbott Laboratories (ABT) - The Globe and Mail
ABTAbbott Laboratories Stock Price and Quote - Finviz
Abbott Laboratories Stock Price Forecast: Where Analysts See the Stock Going by 2027 - TIKR.com
Abbott Labs stock to acquire Exact Sciences for $21 billion By Investing.com - Investing.com Nigeria
Deal Dispatch: Abbott, TPG And Lonza Make Major Moves, M&M Custard And New Fortress Energy Struggle - Benzinga
Abbott Laboratories: Not Passing The Test After Buying Test Maker Exact Sciences (ABT) - Seeking Alpha
Abbott to acquire Exact Sciences in $21 billion deal, aiming to lead in fast-growing cancer diagnostics market - Medical Economics
Abbott’s $21B Exact Sciences buy reveals future strategy - MedTech Dive
Abbott Laboratories to acquire Exact Sciences for $23B in largest-ever diagnostics deal - The Business Journals
Abbott Laboratories Acquires Exact Sciences In $23 Billion Deal - Patch
Abbott Labs stock to acquire Exact Sciences for $21 billion - Investing.com India
Abbott Labs stock gains as UBS reiterates Buy rating on Exact Sciences deal - Investing.com India
Abbott Laboratories’ Strategic Acquisition of Exact Sciences: Enhancing Diagnostics Business and Long-term Growth Prospects - TipRanks
Top 2 Healthcare Stocks Every New Investor Should Know - The Motley Fool
Street View: Brokerages downgrade Exact Sciences following acquisition by Abbott - TradingView
Abbott’s colon-screening deal stinks financially - TradingView
Barclays Sticks to Its Buy Rating for Abbott Laboratories (ABT) - The Globe and Mail
Abbott Breaks into Lucrative Cancer Screening Market with $21 Billion Exact Sciences Purchase - The Daily Upside
Abbott's $21B splurge signals long-awaited dealmaking thaw in health tech - Crain's Chicago Business
Madison's Exact Sciences purchased by Abbott Laboratories, Ancient canoe is the region's oldest - WPR
애보트 래버러토리스 (ABT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.34%
0.06%
자본화:
|
볼륨(24시간):